PT  - JOURNAL ARTICLE
AU  - Ole A.W. Haabeth
AU  - Julian J.K. Lohmeyer
AU  - Adrienne Sallets
AU  - Tim R. Blake
AU  - Idit Sagiv-Barfi
AU  - Debra K. Czerwinski
AU  - Abigail E. Powell
AU  - Paul A. Wender
AU  - Robert M. Waymouth
AU  - Ronald Levy
TI  - An mRNA SARS-CoV-2 vaccine employing a novel delivery vehicle with a TLR-9 agonist induces neutralizing antibodies and T cell memory
AID  - 10.1101/2021.04.14.439891
DP  - 2021 Jan 01
TA  - bioRxiv
PG  - 2021.04.14.439891
4099  - http://biorxiv.org/content/early/2021/04/14/2021.04.14.439891.short
4100  - http://biorxiv.org/content/early/2021/04/14/2021.04.14.439891.full
AB  - The SARS-CoV-2 pandemic has necessitated the rapid development of prophylactic vaccines. Two mRNA vaccines have been approved for emergency use by the FDA and have demonstrated extraordinary effectiveness. The success of these mRNA vaccines establishes the speed of development and therapeutic potential of mRNA. These authorized vaccines encode full-length versions of the SARS-CoV-2 spike protein. They are formulated with Lipid Nanoparticle (LNP) delivery vehicles that have inherent immunostimulatory properties. Different vaccination strategies and alternative mRNA delivery vehicles would be desirable to ensure flexibility of future generations of SARS-CoV-2 vaccines and the development of mRNA vaccines in general. Here, we report on the development of an alternative mRNA vaccine approach using a novel delivery vehicle called Charge-Altering Releasable Transporters (CARTs). Using these inherently nonimmunogenic vehicles we are able to tailor the vaccine immunogenicity by inclusion of co-formulated adjuvants such as oligonucleotides with CpG motifs. Mice vaccinated with our mRNA-CART vaccine developed therapeutically relevant levels of RBD-specific neutralizing antibodies in both the circulation and in the lung bronchial fluids. In addition, our vaccine elicited strong and long lasting RBD-specific TH1 T cell responses including CD4+ and CD8+ T cell memory.Competing Interest StatementThe authors have declared no competing interest.